Country: Canada
Language: English
Source: Health Canada
OLMESARTAN MEDOXOMIL
ORGANON CANADA INC.
C09CA08
OLMESARTAN MEDOXOMIL
20MG
TABLET
OLMESARTAN MEDOXOMIL 20MG
ORAL
15G/50G
Prescription
ANGIOTENSIN II RECEPTOR ANTAGONISTS
Active ingredient group (AIG) number: 0152496002; AHFS:
APPROVED
2011-02-15
_OLMETEC_ _®_ _ _ _(olmesartan medoxomil)_ _ _ _Page 1 of 28_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION OLMETEC ® Olmesartan Medoxomil Tablets 5 mg _*_ , 20 mg, and 40 mg Tablets Oral Angiotensin II AT 1 Receptor Blocker ORGANON CANADA INC. 16766 route Transcanadienne Kirkland, Quebec H9H 4M7 www.organon.ca Date of Initial Approval: October 28, 2008 Date of Revision: April 28, 2021 Submission Control No.: 250401 _*5 mg tablet not marketed_ _OLMETEC_ _®_ _ _ _(olmesartan medoxomil)_ _ _ _Page 2 of 28_ RECENT MAJOR LABEL CHANGES Contraindications, Pregnancy and Breastfeeding, November 2020 Warnings and Precautions, Special Populations, Pregnant women, November 2020 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ................................................................ 4 1 INDICATIONS ................................................................................................................ 4 Pediatrics ........................................................................................................................ 4 Geriatrics ........................................................................................................................ 4 2 CONTRAINDICATIONS ................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ....................................................... 5 4 DOSAGE AND ADMINISTRATION ................................................................................ 5 4.1 Dosing Considerations .............................................................................................. 5 4.2 Recommended Dose and Dosage Adjustment.......................................................... 6 4.3 Reconstitution ........................................................................................................... 6 4.4 Administration ........................................................................................................... 6 4.5 Missed Dose ...... Read the complete document